Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 7, 2015, Pages 880-888

  Pugliese, D ^a   Guidi, L ^a   Ferraro, P M ^a   Marzo, M ^a   Felice, C ^a   Celleno, L ^a   Landi, R ^a   Andrisani, G ^a   Pizzolante, F ^a   De Vitis, I ^a   Papa, A ^a   Rapaccini, G L ^a   Armuzzi, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSORIASIS; RETROSPECTIVE STUDY; SMOKING; SURVIVAL; ULCERATIVE COLITIS; AGED; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; RISK FACTOR;

ADALIMUMAB; ADULT; AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940732204     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13352     Document Type: Article

References (32)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn' disease: the accent I randomised trial. Lancet 2002; 359: 1541-9.
2. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
3. Colombel JF, Schwartz DA, Sandborn WJ, et al,. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
4. D'Haens G, Baert F, Van Assche G, et al,.; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
6. Armuzzi A, Pugliese D, Danese S, et al,. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2014; 20: 1368-74.
7. Colombel JF, Sandborn WJ, Ghosh S, et al,. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014; 109: 1771-80.
8. Burmester GR, Panaccione R, Gordon KB, et al,. Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517-24.
9. Lichtenstein GR, Diamond RH, Wagner CL, et al,. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-26.
10. Cleynen I, Vermeire S,. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 496-503.
11. Fiorino G, Danese S, Pariente B, Allez M,. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014; 13: 15-9.
12. Tillack C, Ehmann LM, Friedrich M, et al,. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63: 567-77.
13. Rahier JF, Buche S, Peyrin-Biroulet L, et al,.; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010; 8: 1048-55.
14. Cullen G, Kroshinsky D, Cheifetz AS, et al,. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34: 1318-27.
15. Harrison MJ, Dixon WG, Watson KD, et al,.; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-15.
16. Collamer AN, Battafarano DF,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-40.
17. Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR,. Psoriasis and palmoplantarpustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012; 67: e179-85.
18. Afzali A, Wheat C, Lee S,. The association of psoriasis with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease. Abstract from the 2011 Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation's National Clinical & Research Conference. Inflamm Bowel Dis 2011; 17: S1-100.
19. Torres J, Buche S, Delaporte E, Colombel JF,. Skin side effects of inflammatory bowel disease therapy. Inflamm Bowel Dis 2013; 19: 1086-98.
20. Moran GW, Lim AWK, Bailey L, et al,. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 1002-24.
21. Naldi L, Chatenoud L, Linder D, et al,. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-7.
22. Cleynen I, Van Moerkercke W, Billiet T, et al,. Anti-TNF-induced skin manifestations in IBD patients: role for increased drug exposure? Gastroenterology 2015; 148: S1-108.
23. Soh JS, Yun WJ, Kim KJ, et al,. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. Inflamm Bowel Dis 2015; 21: 832-9.
24. Guerra I, Algaba A, Pérez-Calle JL, et al,. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012; 6: 518-23.
25. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
26. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-8.
27. Sandborn WJ, Gasink C, Gao LL, et al,. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-28.
28. Brand S,. Crohn's disease: Th1, Th17 or both? The change of a paradigm: newimmunological and genetic insghts implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009; 58: 1152-67.
29. Kryczek I, Bruce AT, Gudjonsson JE, et al,. Induction of IL-17 + T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008; 181: 4733-41.
30. Cargill M, Schrodi SJ, Chang M, et al,. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-90.
31. Franke A, McGovern DP, Barrett JC, et al,. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-25.
32. Anderson CA, Boucher G, Lees CW, et al,. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-52.